Galectin-3 和致瘤性抑制-2 (ST2) 是已知的心脏纤维化标志物。我们研究了纤维化标志物对 ST 段抬高型心肌梗死 (STEMI) 患者舒张功能障碍和长期结局的预后价值。我们分析了 GIPS-III 队列中的 236 名患者，并在住院时和 4 个月随访后进行了可用的超声心动图研究和血浆测量。调整后的逻辑混合效应模型显示，随着时间的推移，舒张功能障碍的发生与半乳糖凝集素 3 和 ST2 血浆水平异常之间没有关联。我们观察到半乳糖凝集素 3 (P = 0.75) 和 ST2 (P = 0.85) 值正常与异常的患者在 5 年随访中的生存结果没有差异。总之，半乳糖凝集素 3 和 sST2 与出现 STEMI 的非糖尿病患者舒张功能障碍的发生无关。© 2024。作者。

Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.© 2024. The Author(s).